4109
加捷生醫
+0.05 (+0.45%)11.10120成交張數368.33本益比0.81股價淨值比1.81%殖利率2026-09-16資料日期
綜合損益表公開資訊觀測站申報原值 · 年度(第 4 季累計) · 每一格 = 該期對去年同期的成長率
營業收入2025485年增 -9.6%
毛利率202531.0%最新一期
營業利益率20250.1%最新一期
每股盈餘20250.43年增 -80.1%
| 會計項目 | 走勢 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 營業收入合計 | – | -16.7% | -22.9% | -14.7% | -21.2% | -10.3% | +31.0% | +4.7% | +61.4% | -9.6% | |
| 營業成本合計 | – | -3.2% | -25.1% | -12.7% | -10.4% | -30.6% | +26.8% | +6.9% | +69.1% | -7.9% | |
| 營業毛利（毛損） | – | -40.9% | -16.7% | -19.9% | -52.6% | +100.8% | +39.1% | +1.0% | +47.4% | -13.3% | |
| 營業毛利（毛損）淨額 | – | -40.9% | -16.7% | -19.9% | -52.6% | +100.8% | +39.1% | +1.0% | +47.4% | -13.3% | |
| 推銷費用 | – | -15.4% | -24.6% | -33.0% | +17.0% | -29.9% | +71.2% | +85.2% | -26.5% | -10.6% | |
| 管理費用 | – | +41.6% | -15.0% | -22.5% | -42.0% | +17.5% | +33.0% | +1.0% | -18.2% | +36.4% | |
| 研究發展費用 | – | -71.5% | -34.8% | -10.3% | -91.4% | – | +147.6% | +4.4% | -29.8% | +2.9% | |
| 預期信用減損損失（利益） | – | – | – | – | – | – | – | – | – | -127.5% | |
| 營業費用合計 | – | +3.1% | -20.4% | -28.6% | -17.1% | -5.9% | +53.7% | +41.2% | -23.7% | +6.7% | |
| 營業利益（損失） | – | -256.9% | – | – | – | – | – | – | – | -97.9% | |
| 利息收入 | – | – | – | – | – | +366.0% | +151.0% | +51.2% | +19.1% | +130.6% | |
| 其他收入 | – | -39.5% | +157.6% | -74.5% | +113.8% | -3.7% | +11.8% | +36.7% | -27.9% | +85.9% | |
| 其他利益及損失淨額 | – | -709.2% | – | -112.8% | – | – | – | – | -8.6% | -78.1% | |
| 財務成本淨額 | – | +10.7% | -1.0% | -68.1% | -75.4% | -91.4% | +85.2% | +208.0% | +84.2% | -56.8% | |
| 營業外收入及支出合計 | – | – | – | -110.6% | – | -6.9% | +44.7% | – | -9.6% | -69.2% | |
| 稅前淨利（淨損） | – | -819.3% | – | – | – | – | -188.5% | – | +53.9% | -73.5% | |
| 所得稅費用（利益）合計 | – | -82.0% | -13.6% | -143.0% | – | – | +823.0% | -126.9% | – | -17.0% | |
| 繼續營業單位本期淨利（淨損） | – | – | – | – | – | – | -226.4% | – | +47.0% | -75.9% | |
| 本期淨利（淨損） | – | – | – | – | – | – | -226.4% | – | +47.0% | -75.9% | |
| 透過其他綜合損益按公允價值衡量之權益工具投資未實現評價損益 | – | – | – | +14.3% | -285.4% | – | – | – | -313.0% | – | |
| 不重分類至損益之項目： | – | – | – | – | -285.4% | – | – | – | -313.0% | – | |
| 國外營運機構財務報表換算之兌換差額 | – | – | – | – | – | – | – | -142.2% | – | -101.9% | |
| 後續可能重分類至損益之項目： | – | – | – | – | – | – | – | -142.2% | – | -101.9% | |
| 其他綜合損益（淨額） | – | – | – | +4.8% | -331.3% | – | – | – | -324.0% | – | |
| 本期綜合損益總額 | – | – | – | -217.4% | – | – | – | – | +37.6% | -74.2% | |
| 母公司業主（淨利∕損） | – | – | – | – | – | – | -202.4% | – | +46.6% | -76.2% | |
| 非控制權益（淨利∕損） | – | -298.8% | – | – | – | – | – | – | +66.0% | -61.1% | |
| 母公司業主（綜合損益） | – | – | – | -186.6% | – | – | – | – | +37.4% | -74.5% | |
| 非控制權益（綜合損益） | – | -740.0% | – | – | – | – | – | – | +49.3% | -58.5% | |
| 基本每股盈餘 | – | – | – | – | – | – | -200.0% | – | +33.3% | -80.1% | |
| 繼續營業單位淨利（淨損） | – | – | – | -1000.0% | – | – | -200.0% | – | +32.7% | -80.0% | |
| 稀釋每股盈餘 | – | – | – | – | – | – | -200.0% | – | +32.7% | -80.0% | |
| 採用權益法認列之關聯企業及合資損益之份額淨額 | – | – | – | – | – | – | – | – | -100.0% | – | |
| 與可能重分類之項目相關之所得稅 | – | – | – | – | – | – | – | – | – | – | |
| 備供出售金融資產未實現評價損益 | – | -100.0% | – | – | – | – | – | – | – | – |
金額為公司申報原值除以一千(百萬元,四捨五入),每股金額為元。年度為第 4 季的年初至今累計數。走勢條是歷史各期的相對大小,藍為正、綠為負。年增以去年同期為基期,基期非正數或變動超過十倍時不列。 權益變動表在申報資料分頁。